eton pharmaceuticals, inc. is a deer park, illinois-based pharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing the u.s. food and drug administration’s 505(b)(2) regulatory pathway. our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
Company profile
Ticker
ETON
Exchange
Website
CEO
Sean E. Brynjelsen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
371858472
ETON stock data
Latest filings (excl ownership)
8-K
Unregistered Sales of Equity Securities
18 Apr 24
S-8
Registration of securities for employees
26 Mar 24
10-K/A
2023 FY
Annual report (amended)
22 Mar 24
8-K
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
22 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
8-K
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
21 Feb 24
8-K
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
2 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
9 Nov 23
Transcripts
ETON
Earnings call transcript
2023 Q4
14 Mar 24
ETON
Earnings call transcript
2023 Q3
9 Nov 23
ETON
Earnings call transcript
2023 Q2
10 Aug 23
ETON
Earnings call transcript
2023 Q1
12 May 23
ETON
Earnings call transcript
2022 Q4
16 Mar 23
ETON
Earnings call transcript
2022 Q3
11 Nov 22
ETON
Earnings call transcript
2022 Q2
12 Aug 22
ETON
Earnings call transcript
2021 Q1
12 May 22
ETON
Earnings call transcript
2021 Q4
17 Mar 22
ETON
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 22.07 mm | 22.07 mm | 22.07 mm | 22.07 mm | 22.07 mm | 22.07 mm |
Cash burn (monthly) | (no burn) | (no burn) | 193.00 k | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 1.31 mm | n/a | n/a | n/a |
Cash remaining | n/a | n/a | 20.76 mm | n/a | n/a | n/a |
Runway (months of cash) | n/a | n/a | 107.5 | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Mar 23 | Riedel Norbert G | Stock Option Common Stock | Grant | Acquire A | No | No | 3.47 | 25,000 | 86.75 k | 134,555 |
3 Mar 23 | Maier Paul V | Stock Option(Right to buy) Common Stock | Grant | Acquire A | No | No | 3.47 | 25,000 | 86.75 k | 134,555 |
3 Mar 23 | Jennifer McKie Adams | Stock Option Common Stock | Grant | Acquire A | No | No | 3.47 | 25,000 | 86.75 k | 103,133 |
3 Mar 23 | Casamento Charles J | Stock Option Common stock | Grant | Acquire A | No | No | 3.47 | 25,000 | 86.75 k | 134,555 |
3 Mar 23 | Brynjelsen Sean | Stock Option Common Stock | Grant | Acquire A | No | No | 3.47 | 350,381 | 1.22 mm | 1,951,881 |
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
22 Mar 24
Eton Pharmaceuticals Acquires Exclusive U.S. Rights To PKU GOLIKE® From Relief Therapeutics, Expects To Be Accretive To Earnings In 2024
22 Mar 24
Recap: Eton Pharmaceuticals Q4 Earnings
14 Mar 24
Eton Pharmaceuticals Q4 2023 GAAP EPS $(0.09) Misses $(0.04) Estimate, Sales $7.313M Miss $7.700M Estimate
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Press releases
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
22 Mar 24
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
22 Mar 24
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
14 Mar 24
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
29 Feb 24
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
21 Feb 24